SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " make " 13,927 found 🔀 AI-powered Shuffle
Elisee Junior St. Preux Signs With Evoke Entertainment (EXCLUSIVE)
Filmmaker Elisee Junior St. Preux has inked with Evoke Entertainment for management, Deadline can report exclusively.
Stillwater’s early start for school is big challenge for football, fall sports
Learn why Stillwater is starting early and how teams are trying to make adjustments.
Take an 8-Minute Gameplay Tour of the Remade Havana in Assassin's Creed Black Flag Resynced
Join Assassin's Creed Black Flag Resynced lead level designer Jean Strachen as she takes you on an eight-minute gameplay tour of Havana. See what it looks like now in the gorgeous new remake that will be released for PC, PS5, and Xbox Series X|S on July 9.
Xprize founder says 'humans behave better when they’re being watched'
Peter Diamandis is the latest tech executive to argue that global surveillance will make the world a better place, following Larry Ellison's comments in 2024.
Charles to join Circle Cinema Walk of Fame
Cherokee filmmaker Jeremy Charles will soon have his name set in concrete outside a storied movie theater with three other Oklahomans honored by the Circle Cinema for work in film
Cannes Lions Entertainment Awards: Adidas Takes Home Grand Prix for Oasis ‘Original Forever’ Collaboration
The 2026 Cannes Lions International Festival of Creativity recognized the best creative campaigns across entertainment, design and craft categories. Sports apparel and footwear maker Adidas’ tie-up wi...
Cannes Lions Entertainment Awards: Adidas' Oasis Collab Wins Grand Prix
The 2026 Cannes Lions International Festival of Creativity winners across entertainment, design and craft categories were announced. Sports apparel and footwear maker Adidas' tie-up with English band Oasis winning the top prize in the Entertainment Lions category.
Volkswagen reportedly planning to axe 100,000 jobs
Volkswagen, one of the world’s largest automakers, is reportedly planning to axe as many as 100,000 jobs over the next few years, representing 15% of its global workforce.
Bungie layoffs revealed to have affected nearly 300 jobs at Destiny 2 maker
Sony said this week it had cut nearly the entire Destiny 2 development team…
Sweden and WHO launch new long-term initiative to transform Ukraine’s health system
WHO and the Swedish International Development Cooperation Agency (Sida) have launched a new multi-year cooperation project to support the long-term recovery and transformation of Ukraine’s health system. The new project, “Ukraine’s Health System Transformation Initiative: Strengthening Health Governance, Health Financing and Service Delivery for Long-Term Recovery”, was launched at the Ukraine Recovery Conference 2026 in Gdansk, Poland on 26 June, and will run from June 2026 to 2029. Sweden will contribute approximately US$ 26 million (240 million Swedish krona) to support this project. This contribution forms part of Sweden’s broader support to Ukraine through the Team Europe approach, which brings together the European Union, its Member States, and key partners such as the European Commission’s Directorate-General for Enlargement and Eastern Neighbourhood and Enabel, and WHO as lead health agency, to support Ukraine’s recovery, reform agenda and European integration.“Ukraine’s health recovery cannot be measured only by what is rebuilt, but by whether people can count on the health system when they need it most. The scale of the task is immense, with health reconstruction and modernization needs estimated at US$ 19.4 billion over the next decade. Sweden’s US$ 26 million contribution to Ukraine’s Health System Transformation Initiative is a timely investment in the institutions, financing and services that will support Ukraine’s long-term recovery and European integration. WHO remains a trusted partner of the Government of Ukraine in advancing this process. I am deeply grateful to Sweden for its consistent support and partnership,” said Dr Hans Henri P. Kluge, WHO Regional Director for Europe. More than 4 years of war have placed unprecedented pressure on Ukraine’s health system, creating 3 interconnected challenges. The first is responding to the immediate consequences of the war and the urgent health needs of the population. The second is recovering and modernizing health services today. The third is continuing reforms and aligning the health system with European standards in the context of Ukraine’s future accession to the European Union. The war has led to large-scale population displacement, an increasing need for trauma care and rehabilitation, and shortages of health workers. High out-of-pocket payments in Ukraine make access to health services more difficult. Around 46% of total health expenditure is paid directly by individuals, placing a significant financial burden on many households and underscoring the need for reforms in health financing. Older people, persons with disabilities, women, children and veterans continue to face the greatest difficulties in accessing health services. “Ukraine is demonstrating that health system transformation can continue even during war. Ukraine is also continuing to align its health system with European norms and standards. WHO is committed to supporting Ukraine on this journey. We provide technical support, help coordinate partners’ efforts and support the institutional changes needed to strengthen the system. We are grateful to Sweden for its support. Through this partnership, we can help Ukraine build a more resilient, accessible and people-centred health system,” said Dr Jarno Habicht, WHO Representative in Ukraine. About the Health System Transformation InitiativeThe new initiative will support Ukraine through 3 interconnected areas: strengthening governance and coordination of health sector reforms through more inclusive coordination platforms and structured policy dialogue; transforming service delivery by reinforcing a primary health care-centred model that integrates family medicine, nursing and midwifery; and improving financial sustainability by supporting reforms that ensure the long-term viability of the national health system and reduce out-of-pocket payments for households. Overall, these reforms are expected to make the health system more coherent and easier to navigate, improve the quality and continuity of care, and ensure more equitable access to services, particularly for those who need them most. They will also support Ukraine’s progress towards a more modern health system aligned with European standards. “We are convinced that long-term recovery is not possible without strong, high-quality, person-centred health services that are accessible to everyone. Our partnership with WHO is designed to support deep and lasting systemic changes. Investments in human capital especially autonomous midwives, whose role for maternal, newborn and adolescent sexual and reproductive health cannot be understated, stronger governance, digital transformation and the financial sustainability of the health system are investments in Ukraine’s future. We are proud to support this process,” said Malin Perhult, the Head of the Ukraine Unit at Sida. Focus throughout implementation will be given to the most vulnerable population groups, including older people, women and children, and persons with disabilities, who have been affected by the war and face greater health-care needs. The initiative will be implemented in close cooperation with the Ministry of Health of Ukraine, the National Health Service of Ukraine, the Public Health Centre of Ukraine, regional authorities and international partners. This project will help Ukraine move towards a system where everyone can access the health care they need. It will strengthen primary care, make the health finance system more stable and predictable, and reduce the out-of-pocket costs that Ukrainians face when using health services. As a result, the Ukrainian health system will become more aligned with European standards and more sustainable in the long run.
Lincoln International CEO on why the firm went public — and what’s ahead for dealmaking
Lincoln International makes its public debut as dealmaking is poised for a resurgence, with the firm's client engagement letters up 40%.
Happy birthday, 2000 Year Old Man. Mel Brooks is turning 100
The 2000 Year Old Man is turning 100. Mel Brooks on Sunday will celebrate his centennial birthday. The comedian and filmmaker has been awaiting the milestone. Earlier this year, Judd
St. Norbert, FVTC partner to make business degree transfer 'seamless'
St. Norbert and Fox Valley Technical College are joining forces to make getting a bachelor's in business at SNC easier.
NTT DATA | Transforming Data Into Exceptional Fan Experience
We worked with Penske Automotive Group to create a mobile application to amplify the fan experience and make the iconic Indianapolis Motor Speedway a smart venue through NTT Smart Solutions.
Valve Would "Love to Make the Steam Machine More Affordable" - Just Don't Expect It "Any Time Soon"
If memory prices go down - and that's a big if.
SpaceX employees get rich off IPO while Blue Origin workers miss out
Three ex-employees of Jeff Bezos' rocket maker said Blue Origin's approach to equity left them with stock options that are essentially worthless.
Williams to begin Wimbledon comeback against Joint
American superstar Serena Williams will make her highly-anticipated singles comeback at Wimbledon against Australia's Maya Joint in the first round.
Intel’s Chip Business Shows Signs of Life After Years of Struggle
It is the centerpiece of President Trump’s drive to make more chips in the United States, but the company still has a long way to go before it can be called a complete turnaround.
Professor Willow’s Birthday Research
Starts Tuesday, July 21, 2026, at 10:00 AM Local Time Ends Tuesday, July 21, 2026, at 8:00 PM Local Time Wish Professor Willow a very happy birthday with Professor Willow’s assistant Pikachu! This adorable Pikachu makes their Pokémon GO debut as part of the Willow’s Birthday Research event along with GO Snapshots, raids and more […]
Reasoning For Pitching Prospect's Absence From Rehab Assignment Revealed
Left-handed pitcher Ricky Tiedemann didn't make an appearance in his rehab assignment in Single-A due a separate injury than the one he's recovering from.
Phillies’ Byron Buxton rumor won’t come true, but another trade with Twins still makes sense
Who else could the Phillies land?
Three Chicago Bears make CBS Sports’ Top 100 NFL Players of 2026 List
With the NFL on a break, get ready for list season, and CBS Sports just dropped their Top 100 Players, and three Chicago Bears made the cut.
It's Xbox's turn (again), as console prices keep going up
Microsoft announced a price hike for the Xbox Series consoles today, the third in little over a year. Effective August 1, the Xbox Series S, which launched in 2020 for $300, will cost $500 in the U.S. The Xbox Series X, which launched in 2020 at $500, will go for $800. This follows a round of PlayStation 5 price increases from Sony this spring, and a slow-motion increase for Nintendo’s Switch 2, which will kick in in the U.S. in September. (Mind you, there were also eight video game industry price hikes in six months of 2025). The chart up top shows the sudden ascent of console prices over the past year, a sudden surge in an already unusual hardware generation. Prices had been flat for years, now “up” is the new “flat.” Game console prices used to go down across the length of a console generation, but not this time around. Microsoft’s explanation for the new price hike today: We hoped another price increase would not be necessary, and we have spent the last several months working with suppliers on options. Unfortunately, console storage and memory prices have increased by more than 2.5x and we expect another doubling by the fall of 2027. The entire consumer electronics industry is struggling with the current components crisis, but the effects are particularly hard on consoles. Unlike phones, computers, speakers, and other consumer devices, consoles are typically not sold at a profit, but instead for less than they cost to make. This is an issue well beyond game consoles. Apple announced price hikes on its computers and tablets today as well. Game File is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe Item 2: Brutal Bungie cuts Bungie laid off “most” of its Destiny development team and some developers who worked on Marathon, the newest game from the struggling Sony-owned studio. A WARN notice issued by Sony to Washington State, where Bungie is based, tallied cuts impacting 292 workers, effective next month. That’s strictly for Bungie/Sony jobs in Washington and wouldn’t account for any elsewhere. The video I clipped below shows the redacted list of Bungie cuts filed to Washington State officials. As you’ll see, I had to scroll for a while… In a note emailed to PlayStation workers and published online, PlayStation game studios chief Hermen Hulst offered the following explanation for these latest cuts at Bungie: This is painful news, especially for talented colleagues whose roles have been eliminated. This decision was made only after extensive discussion and careful consideration, and I want to provide some context on how we arrived here. Over the past several months, together with Bungie leadership, we reviewed the studio’s long-term direction, development priorities, resource needs, and role within our broader portfolio strategy. We explored multiple alternatives before concluding that a reduction was necessary to align the studio’s resources with its current priorities and long-term goals. In 2022, Sony bought Bungie for $3.7 billion. The studio’s marquee game, the multiplayer live service shooter Destiny 2 was losing popularity at the time. Its next game Marathon, released earlier this year, has been well-reviewed but had a slow start. Bungie is renowned for making great shooter games, and Destiny fans have mourned the wind-down of Destiny 2. They’ve also expressed bewilderment over reports that Destiny 3 is not, per Bloomberg, immediately in the cards.
Baxter Health Heart and Vascular Clinic Welcomes Brandi Watson, APRN
Baxter Health is proud to welcome Brandi Watson, APRN, to the Baxter Health Heart and Vascular Clinic. Watson joined the team on May 15 and is currently accepting new patients. Watson brings more than 25 years of experience caring for some of the most critically ill patients. Much of her career has been spent in intensive care settings, where she learned to make fast, high-stakes decisions for patients whose lives depended on getting the right care at the right moment. That kind of experience, which is gained through years at the bedside, is exactly what heart and vascular patients need from a provider.
President Trump Signs Executive Order Advancing Regenerative Agriculture as Part of Make America Healthy Again Agenda
President Trump Signs Executive Order Advancing Regenerative Agriculture as Part of Make America Healthy Again Agenda
Dolly Parton makes surprise appearance — complete with a joke
Dolly Parton just made a surprise appearance, complete with her trademark humor, amid health issues.
Android 17’s new foldable gaming mode could make flippy phones more fun
A whole half of your screen will be dedicated to touch controls.
YouTube updates Shorts to make it even more like TikTok
Where have we seen these features before?
YouTube Shorts are getting even shorter with an update that lets you double the playback speed
YouTube Shorts is getting a makeover.
WATCH: House Democratic leaders hold hearing on fair elections and voting rights
House Minority Leader Hakeem Jeffries and Democratic lawmakers held a hearing Thursday on defending fair elections and voting rights.
Tennessee court temporarily blocks state health officials from sharing undocumented ill children’s information
The “state cannot go forward with the policy” until the judge makes a final decision, said the head of the Tennessee Justice Center.
Shockwave Medical announces new studies evaluating carotid IVL platform
Carotid artery disease causes up to 30% of all strokes, but severely calcified lesions can make treatment quite complex. The hope is that IVL can be as successful in this area as it has been in the treatment of coronary and peripheral artery disease.
Business Council deliberations continue with four bill drafts
Lawmakers on the Joint Appropriations Committee spent another day diving through the Wyoming Business Council’s dealings. This time, they also reviewed draft bills that would influence how the council operates.
Local entrepreneurs, aspiring business owners gain connections, resources at 4th annual expo
Small business owners and aspiring entrepreneurs convened in Downtown Memphis to make connections and grow Thursday morning at the 2026 Small Business Expo.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
The Politics Hour: The big winners in MD's primary elections
Leading Democratic nominee for Montgomery County Executive Will Jawando talks about his message to voters, dark money, and data centers. Plus, Tara Jackson wins the Democratic nomination for Prince George's County State's Attorney and WAMU's Alex Koma on D.C. lawmakers greenlighting the budget.
Dunleavy vetoes some health and education increases approved by Alaska lawmakers
Alaska Gov. Mike Dunleavy canceled funding increases for a variety of state health and education programs on Wednesday, vetoing a combined $57.8 million in general-purpose money from state budget bills passed by the Legislature.
Renewed Dansby Swanson makes Cubs history with 15 RBI across 3 games vs. Mets, including 11 in doubleheader
This Simple Trick Can Make Your Coffee Taste Way Better, Says Physics
If you love pour-over coffee it could serve you well to change how you pour.
Samsung Reportedly Starts OLED Panel Production for Apple’s First Foldable iPhone
Apple reportedly cleared Samsung Display to make OLED panels for its first foldable iPhone, with hinge issues still shaping launch timing.
Fed Rule Effectively Puts Automaker Polestar Out Of Business In The U.S.
Volvo’s upscale electrified division pulls the proverbial plug on future U.S. sales because of its ties to China.
Two NC lawmakers, a Democrat and a Republican, push Congress to delay SNAP changes
Above the federal penalty threshold, NC could owe $140M a year, putting at risk a program that helps over 1.2 million North Carolinians.
Spent 3 days at Acadia National Park; biggest mistakes we made
We spent a few days exploring Acadia National Park in Maine. Next time we go, we'll make reservations and avoid mistakes like packing the wrong shoes.
RFK Jr. urged Iowa candidate to make deal to help GOP win House seat, per audio recording
The health secretary urged Iowa Libertarian candidates to drop out of key races to help Republicans keep control of Congress, according to interviews and a recording obtained by The Post. The effort highlights mounting GOP anxiety over the battle for the House.
Galaxy Z Fold 8 release date leaks, hands-on impressions make ‘Ultra’ seem pointless
Continued Galaxy Z Fold 8 leaks are revealing more and more about Samsung’s upcoming foldable series, this time including some...
Sony A7R VI review: A huge speed boost makes this a nearly perfect high-resolution camera
Sony’s A7R VI finally serves up speed and resolution together thanks to the new 67MP stacked sensor.
LaMelo Ball trade grades: The Hornets' logic makes sense, but what is Minnesota's thought process?
Supreme Court sides with big business in Roundup cancer risk fight
The ruling is also a victory for the Trump administration and a defeat for the Make America Healthy Again movement.
Grand Theft Auto VI pre-orders open, but don’t expect a physical copy
The blockbuster launch is expected to dwarf the box office takings of the year’s biggest movies with one industry analyst predicting it could make $1bn within an hour
Supreme Court sides with big business in Roundup cancer risk fight
The ruling is also a victory for the Trump administration and a defeat for the Make America Healthy Again movement.
Supreme Court protects pesticides from some health claims in key Roundup case
The Supreme Court on Thursday restricted Americans’ ability to sue pesticide makers over alleged health harms stemming from their products. In a 7-2 ruling, the court held that some claims that pes…
Make/Films opens new Lancaster city studio in Stadium District
Make/Films — the studio that brought a story about a Garden Spot teacher to movie theater screens nationwide — recently tripled its space with a new studio.
David P. O'Brien
About five years ago, David P. O'Brien had a comfortable position at Marsh & McLennan Cos., where he held the top post at the financial giant's Louisville, Ky., office. Despite the lofty rank, Mr. O'Brien found himself longing to be at a smaller company that had to work a little harder to land business. That desire led him away from Kentucky five years ago and to Cleveland, where he serves as executive vice president at business insurance agency Oswald Cos. "I left Marsh before it was en vogue," he said, referring to layoffs and defections at Marsh over the course of this year that followed accusations of bid rigging at the big firm. Above all, Mr. O'Brien, 38, wanted to work at a company that relied on its inventiveness, rather than its name, for business. He said he has found that at Oswald. "It causes you to be more creative, to be more resourceful," Mr. O'Brien said. For instance, an Oswald client seeking to do business internationally might be directed to the network of offices abroad run by competitors such as Marsh and Aon Risk Services Inc. "We're going to use whatever access into the market that makes the most sense for our clients," he said. Of course, using such a strategy can be dangerous for Oswald if its client decides to further a business relationship with one of the firms Oswald recommended. "That's the obvious question and why it's nontraditional," he said. "I think if we're good, and if we're bringing value to the client, then there's no risk. I'm not threatened by it." Imaginative business solutions of that type made his career move to Oswald from Marsh worthwhile. "It's very much a challenge," he said. "It helps you keep your edge. I'm all for the competition." John Jacunski, currently vice president and corporate controller at York, Pa., paper company PH Gladfelter Co., met Mr. O'Brien four years ago when Mr. Jacunski was at WCI Steel Inc. in Warren. So impressed was he with Mr. O'Brien's work for WCI that Mr. Jacunski has retained the Oswald executive at PH Gladfelter. "He's a young guy for the position he has, but he's done a great job for us," Mr. Jacunski said. Among his roles at Oswald, Mr. O'Brien leads the firm's client retention efforts and also serves as director of its property and casualty group. "You don't have the same human resources," he said of the job jump to Oswald. "You don't have, obviously, the safety net a big company has." But sometimes, it can be difficult to ascertain individual contributions when working at a big company. "I wanted to be able to see the end results of my work and my efforts," Mr. O'Brien said.
After my divorce, I rebuilt my life, starting with friendship
After my divorce, I felt lonely and had to make new friends. I learned a lot about friendship — and myself — in the process.
Dolly Parton Makes Surprise Appearance Following Health Issues
Dolly Parton made a surprise appearance at the grand opening of her travel stop in Tennessee just one month after she canceled an upcoming Vegas residency due to health concerns.
How anti-LGBTQ policies can affect business
Despite federal backlash against corporate DEI policies, companies that invest in inclusivity know that it makes economic sense.
Ebola response highlights value of African science
With African scientists leading the way in the latest Ebola response, Catherine Kyobutungi makes the case for long-term investment.
How should European scientists respond to the US AI kill switch?
Earlier in June, Europe’s worst fears of technological dependence were confirmed when the White House ordered the AI firm Anthropic to stop non-US citizens using its leading models. This kill-switch moment crystalised anxieties in Brussels that the continent, lagging the US on the creation of leading-edge AI models, is now a technological of vassal of Washington. The shock has specific implications for European scientists and universities. Some governments are now worried that with AI being integrated into labs, Donald Trump now has his finger hovering over an off switch for European science. “Having restrictions on this tool, it can have an impact on our own research,” said France’s research minister, Philippe Baptiste, at the VivaTech conference in Paris on June 18.Baptiste, himself a former academic, said that colleagues in mathematics had recently warned him they were now cut off from leading-edge US models, risking their work. “This model is not available anymore now because of the US restriction, and for the first time this had an impact on mathematics,” a field where large language models (LLMs) are making a significant contribution, said Baptiste. So, should European scientists avoid relying on US models in the future? Or would this be a self-harming overreaction? And how is AI being used in science, anyway? What happened?On June 12, it emerged that Washington, citing cybersecurity concerns, had ordered Anthropic to stop non-US citizens using two models: Claude Mythos 5, and Claude Fable 5, a version of Mythos but with guardrails to prevent abuse. Anthropic said Washington’s concerns were overblown. But forced to follow the order, yet with no way to check who was using the models, the company suddenly shut down access for everyone, US citizens included. There’s still no agreement on how to restore broad access. But last week, Bloomberg reported that select US companies, and the US government, still had access to Mythos despite the ban, but the EU’s cybersecurity agency Enisa had been shut out. Class division of researchersIn the longer term, access outside the US should be restored, said Marcel Salathé, co-director of the AI centre at the Federal Polytechnic School of Lausanne (EPFL), because a permanent restriction would be financially ruinous to US AI firms. “Even Trump will eventually budge to economic pressure,” he said.However, US AI firms might end up operating rather like banks, doing due diligence on users of their leading-edge AI models, he went on.European scientists are unlikely to fall foul of such checks, he said. But having a Chinese postgraduate in their lab, or doing a type of research the US disapproved of, could potentially result in access being denied. “It will create a sort of class division of researchers,” he said. More than frontier modelsHowever, successfully deploying AI in science is about far more than just having access to leading LLMs such as Mythos.Instead, many science-specific tools, most famously Alphafold, which predicts protein folding structures, require “far less” computing power to train than frontier models, well within the capabilities of European supercomputers, according to a recent analysis by the Arq Foundation, a Brussel-based AI think tank. Instead, tools such as Alphafold are possible because certain fields, like protein folding, weather prediction or astronomy, have large, clean, standardised datasets that can be used to train predictive models. Rather than compute, “data is the central constraint for AI for science,” the report says. For example, a less powerful physics model trained on CERN’s data “will be more valuable than the best model without certain data,” said Bengüsu Özcan, author of the report. European advantage?Europe could therefore steal a march by using its scientific data and infrastructure to create models US digital giants cannot. “They might actually match or go even beyond what these big [US] companies are doing,” said Özcan.Indeed, some European start-ups hope to create automated testing labs to create the kind of standardised data that could speed up the discovery of new materials. Materials scientists say there’s currently too little data to train models. AI scientistsHowever, even if the bottleneck for AI in science is often data, rather than compute, being at the mercy of the US for LLM access could still become a problem for European scientists. A new class of “AI scientists” based on leading LLMs is also emerging, Özcan’s report says.Unlike domain-specific tools like Alphafold, these try to automate day-to-day scientific work, by providing an overarching tool that coordinates specific models to synthesise existing literature, generate hypotheses or run analysis of data. The problem for Europe, however, is that these tools are sometimes based on US leading models. Google Deepmind’s AI Co-Scientist, for example, is built on Google’s Gemini LLM. Systematic failureThese scientific automation tools are still in their early stages, and still exhibit “systematic failures on scientific tasks,” Özcan’s report says. One of the problems is that the messy, day-to-day process of scientific discovery is largely not documented, meaning LLMs don’t have a good source of data to learn how scientists actually work. Meanwhile, some tasks, such as literature synthesis, don’t typically require access to leading edge models.However, the performance of AI scientific assistants could improve as companies such as Google pour resources into developing them. Rely on US“Unfortunately, for scientific assistants, there is not much we can do right now except rely on US frontier AI,” said Antoine Bosselut, a natural language processing expert based at EPFL. Chinese-built open models, which can run on local computers, lessening the risk of a shutdown, are touted as one alternative to US dependence. There’s also Mistral, once seen as Europe’s main AI hope, but the Paris-based company has seen its recent models fall behind in performance. But the Chinese alternatives are generally not as capable as US frontier AI models, said Bosselut, unless paired with fiddly, custom tools that allows them to act as independent agents. “Most scientists do not have the time,” he said. Don’t jump ship yetAlthough the kill switch moment is seen a warning shot for European scientists, it doesn’t mean labs should abandon US AI tools immediately. “I do not think the right response is simply to abandon US-based models and systems under the banner of sovereignty or independence,” said Mattias Björnmalm, secretary general of the Cesaer university association. “That would be an overreaction.”Related articlesEuropean sovereignty in AI requires ‘ugly trade-offs,’ say experts Robotic lab start-up makes case for €500M EU-funded materials testing facilityAI in science: is it useful? Instead, European researchers need to ask themselves whether they’re becoming dependent on technology that could be turned off in Washington, said Özcan. “They might not see this today, but they should really start asking this question,” she said. European researchers need a plan B, said Salathé. “I would recommend to every researcher, very proactively explore alternatives.”Own toolsIn addition, Björnmalm and others want European research institutions to develop their own scientific AI tools.Instead of signing AI deals with US digital giants, European universities should be using this money to create their own models, which may end up being superior for research, said Sabine Leonelli, an expert on the use of AI in science at the Technical University of Munich. “Universities in Europe seem to be happy to sign commercial contracts with US companies on the assumption [their AI tools] are better,” she said. But US frontier LLMs are typically opaque, and have been developed without independent scientific input, she said. “This is not good enough for science.”Last year, Swiss researchers released Apertus, an LLM designed to be completely transparent, from its development methods to its training data. The idea is that this makes scientific tools built on top of the model far more reproducible than with closed, commercial alternatives.“Europe needs more of this: serious capacity-building that gives researchers, universities and companies credible options,” said Björnmalm.
Highest June minimum temperature record broken in Cardiff as ‘savage’ heatwave continues
Thermometer only drops to 23.5C overnight in Welsh capital as climate crisis makes such extreme temperatures more severe and more likely
New Galaxy S23 software update makes it more secure
Samsung has started rolling out the June 2026 security patch to the Galaxy S23, Galaxy S23+, and Galaxy S23 Ultra.
Memphis People in Business for June 25, 2026
A look at promotions, hirings, movers and newsmakers in the Memphis area business scene
Esquire First Look: Robert Eggers Reveals Aaron Taylor-Johnson in Werwulf
The filmmaker behind ‘Nosferatu’ and ‘The VVitch ‘explores the historical inspiration behind his tale of a man struggling with his inner beast.
A Generational Shift in New York City Politics
Younger voters want to remake the system, not fix it, a former party official said. Their candidates won on Tuesday.
Francesco Bagnaia makes Aprilia MotoGP switch after Ducati exit
More puzzle pieces fall into place as Aprilia finalises 2027 line-up
Tracy: "The Chicago Bulls were trying to make a trade. …
Tracy: "The Chicago Bulls were trying to make a trade. …
Only Donald Trump could make America’s special 250th birthday all about him
The milestone called for the epic vision of a JFK or the soaring oratory of a Barack Obama. Instead it got a Trump rally
Stubborn, arrogant, a genius: France’s De Gaulle epic shows up the tepidity of our politics
The man who led Free France during Nazi occupation was single-minded to the point of obstinacy. But he believed in his own power to make history, says Guardian Europe writer Alexander Hurst
NATO’s Leader Makes His Case to Trump for Preserving the Alliance
Using charts, Secretary General Mark Rutte appeared to defuse the president’s anger by showing that European countries were “equalizing” defense spending with the U.S.
Micron and Qualcomm forecasts ignite $400 billion AI chip stock rally
Shares of chipmakers surged late on Wednesday, adding over $400 billion in market value after strong forecasts from Micron Technology and Qualcomm breathed fresh life into Wall Street's recently waning AI stock rally.
Reese Witherspoon's boyfriend makes red carpet debut at 'Elle' premiere
Reese Witherspoon and her financier beau, Oliver Haarmann, have set a new bar in their relationship.
The biotech founder asking why good science gets stuck
As an undergraduate, Alinta Furnell led student societies, pitched startup ideas and built biotechnology ventures. Now, the UNSW alumna is investigating one of innovation’s biggest challenges – why so many scientific breakthroughs never make it beyond the lab.
Trump-endorsed de la Espriella declared winner of Colombia presidential election
He defeated progressive lawmaker Iván Cepeda by 1 percentage point
Trump-endorsed de la Espriella declared winner of Colombia presidential election
He defeated progressive lawmaker Iván Cepeda by 1 percentage point
Newsom visits SF Mexican restaurant for 1st meeting with Becerra
The two lawmakers chatted over a mid-morning meal on Wednesday.
IHSA reacts as lawmakers propose bill requiring oversight on girls' sports impact
A new bill in Springfield would seek to overturn an IHSA decision to change the girls' high school flag football season
Diamondbacks Make a Decision on Carlos Santana
Carlos Santana’s brief stint in Arizona appears to be over after the Diamondbacks designated the veteran first baseman for assignment Wednesday.
Reese Witherspoon makes first public appearance with boyfriend Oliver Haarmann
Reese Witherspoon made her first public appearance with financier boyfriend Oliver Haarmann at the 'Elle' premiere in New York City.
Usher says tour with Chris Brown is about more than 2 stars. He makes the case for R&B in stadiums
Usher is launching a stadium tour with Chris Brown and says Brown's legal troubles never influenced his decision.
Anthropic Veterans’ Startup Seeks to Help Scientists Develop Their Own AI
Mirendil raises $200 million from Andreessen Horowitz and Kleiner Perkins to make AI that can do the job of an AI engineer.
Jeremiah Smith earns first 99 launch rating in EA Sports College Football
Ohio State wide receiver Jeremiah Smith makes history as the first player to earn a 99 rating at launch in EA Sports College Football.
Jeremiah Smith earns first 99 launch rating in EA Sports College Football
Ohio State wide receiver Jeremiah Smith makes history as the first player to earn a 99 rating at launch in EA Sports College Football.
Google's Gemini 3.5 Pro release slips to July
Google's next big AI model is coming later than promised, but the company is trying to use the extra time to make it better.
Rand Paul questions USPS business model as postmaster general seeks reform
Kentucky Senator Rand Paul is questioning the United States Postal Office’s (USPS) business model following the appearance of the agency’s postmaster general before lawmakers.
Science Day 2026 at the HLPF: The science-policy imperative in the final stretch to 2030 and beyond
Science Day convenes scientists, policymakers and societal actors at the HLPF to examine science's role in accelerating SDG delivery to 2030.
From The Sports Desk: Cristiano Ronaldo makes history and joins in World Cup scoring barrage
Ronaldo scored twice yesterday against Uzbekistan, which made him the first player to score in six World Cups, from 2006 through this tournament.
From The Sports Desk: Cristiano Ronaldo makes history and joins in World Cup scoring barrage
Ronaldo scored twice yesterday against Uzbekistan, which made him the first player to ever score in six different World Cups, from 2006 through this current tournament.
Startup’s strategy challenges EV industry assumptions
A new EV startup led by a former Amazon executive is betting that a low-cost, highly customizable pickup starting at just under $25,000 could help it achieve something that has eluded many EV startups: profitability, CNBC reports. The central goal for Slate Auto and CEO Peter Faricy is to make a full-size, practical truck accessible […]
HART HAS UNFINISHED BUSINESS AT NORWALK
BROWNSBURG, Ind. (June 24, 2026) – Josh Hart knows what it’s like to make it to the final round of NHRA Top Fuel competition at Summit Racing Equipment
Exploring Heat’s search for shooters and what makes sense with roster, finances
A look at the Heat’s search for shooters to put around Giannis Antetokounmpo and Bam Adebayo
Mike Quigley to make mayoral bid official with Saturday kickoff
U.S. Rep. Mike Quigley is making his long-anticipated run for Chicago mayor official this weekend.
Google’s New $100 Speaker Makes a Weak Case for Gemini in the Home
The Google Home Speaker is the first new device of its kind to come from Alphabet Inc. in six years. In that time, Google has reshaped itself as an industry leader in artificial intelligence, with its Gemini platform now ubiquitous across consumer hardware like smartphones and web services like Search, Workspace and YouTube.
Muni Long underwent double lung transplant in life-saving surgery
R&B hitmaker Muni Long is finally opening up about the life-threatening medical issue that forced her to cancel concerts last year.
Will Smith, Jada Pinkett Smith make rare appearance in Paris outing
A decade after their separation, Will Smith and Jada Pinkett Smith still make time for each other.
Marco Palestra to Chelsea: Why Atalanta wing-back's dribbling and running power makes him a fit for the Premier League
Prime Day 2026: Top Savings on Anker, Beats, TVs, and More Accessories
Earlier this week we highlighted some of the best Apple-related product discounts that you can find on Amazon during Prime Day, and now we're focusing on third-party accessory markdowns during the event. In this article you'll find all the best accessories for charging, smart homes, smartphones, and more. Note: MacRumors is an affiliate partner with some of these vendors. When you click a link and make a purchase, we may receive a small payment, which helps us keep the site running.
Star Fox Review: Can't quite teach an old Fox new tricks
The Switch 2 Star Fox remake comes with high-effort visuals and a fun battle mode, but its campaign feels stuck in the past.